BioBusiness

The proposed spin-off of Sandoz into an independent entity has been approved by Novartis’ board of directors.

The partnership will see Flagship and Pfizer work to create a new pipeline of innovative medicines.

The expanded deal, now potentially worth more than $1.2 billion, will work to develop in vivo therapies, including sickle cell disease.

Novartis’ acquisition of biotech company DTx Pharma boosts its neuroscience pipeline and expands its capabilities in RNA-based therapeutics.

The goal for Upperton is to become fully operational by Q4 of 2023 for development and non-GMP manufacturing and a target start of GMP operations in January 2024.

After the completion of the merger, the company is expected to operate under the name “Neurogene Inc."

Westlake’s third fund of $450 million will be used to grow early stage biotechnology companies.

German manufacturer metabion is conducting a multi-million euro expansion of its oligonucleotide manufacturing capacity in Munich East.

Start-ups are plagued with common issues that dramatically decrease their odds of achieving investor funding.

Exploring new fields can bring novel antibody candidates to the pipeline.

In addition, Caribou will maintain full ownership and control of its pipeline of allogeneic CAR-T and CAR-NK cell therapies.

Camena Bioscience has completed $10 million in Series A financing on the back of growing demand for DNA synthesis.

Chime Biologics, Leads Biolabs, and BeiGene have formed a three-way collaboration to advance the development and global manufacturing of Leads Biolabs’ lead mAb candidate, LBL-007.

If we view a change opposite of one’s interest as antithetical to innovation, we risk losing sight of our ultimate goal.

The debate surrounding drug pricing changes rages on.

Donaldson Company’s €136 million (US$148 million) acquisition of Univercells is designed to broaden its portfolio of biomanufacturing solutions.

Mason Ailstock, CEO of the Rowen Foundation, discusses incubators and their potential to promote innovation.

Image analysis algorithms coupled with microscopy techniques can be used to characterize aggregates of therapeutic proteins.

The prestigious award, worth €20,000 (US$22,000), goes to Maurice Michel of the Science for Life Laboratory at Karolinska Institutet, Stockholm, Sweden.

PIF has established Lifera, a new manufacturing entity that will manufacture, stockpile, and supply bio/pharmaceuticals both locally and through partnerships.

India’s Enzene Biosciences is investing $50 Million into a new biopharma manufacturing plant in Hopewell, NJ.

Eli Lilly & Company will pay Verve Therapeutics up to $525 million to advance a lipoprotein gene editing research program.

Advanco’s acquisition of Vantage Consulting Group boosts its position as a provider of independent pharmaceutical serialization solutions.

The collaboration between the Pistoia Alliance and Matador Japan will work to accelerate research and promote access to a global pharmaceutical ecosystem.

There are various challenges associated with the development of CAR-T therapies for solid tumor cancers.